Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Abstract
Although androgen deprivation therapy (ADT) and androgen receptor (AR) signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most patients. This phase I/II trial assessed the safety, pharmacokinetic impact, and efficacy of the glucocorticoid receptor (GR) antagonist mifepristone in combination with enzalutamide for castration-resistant prostate cancer (CRPC).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 02, 2022
- Source ID
- 10.1158/1078-0432.ccr-21-4049
Entities
People
- Amanda K L Anderson
- Anthony V. Serritella
- Daniel Shevrin
- Elia Martinez
- Elisabeth I Heath
- James L Wade
- Joseph Schonhoft
- Russell Z. Szmulewitz
- Theodore Karrison
- Walter M. Stadler
- Yen-Lin Chu
Organizations
- Decatur Memorial Hospital
- Epic Sciences
- NorthShore University HealthSystem
- United States Department of Defense
- University of Chicago
- Wayne State University